Health Technology Assessment Reports for Non-Oncology Medications in Canada from 2018 to 2022: Methodological Critiques on Manufacturers’ Submissions and a Comparison between Manufacturer and Canadian Agency for Drugs and Technologies in Health (CADTH) Analyses

Fatemeh Mirzayeh Fashami (), Jean-Eric Tarride (), Behnam Sadeghirad (), Kimia Hariri (), Amirreza Peyrovinasab () and Mitchell Levine ()
Additional contact information
Fatemeh Mirzayeh Fashami: McMaster University
Jean-Eric Tarride: McMaster University
Behnam Sadeghirad: McMaster University
Kimia Hariri: Mazandaran University of Medical Science
Amirreza Peyrovinasab: Islamic Azad University, Tehran Medical Sciences University (IAUTMU)
Mitchell Levine: McMaster University

PharmacoEconomics - Open, 2024, vol. 8, issue 6, No 4, 823-836

Abstract: Abstract Introduction Identifying key differences between manufacturers’ submitted analysis and economic reanalysis by the Canadian Agency for Drugs and Technologies in Health (CADTH) is an important step toward understanding reimbursement recommendations. We compared economic values reported in manufacturers’ analysis with the CADTH reanalysis and also assessed methodological critiques. Methods Two reviewers extracted data from the clinical and economic reports in publicly available CADTH reports from 2018 to 2022. We used the Wilcoxon rank-sum test to assess the difference between mean economic values, and the Chi-square test to assess the association between the CADTH critique final recommendations. Results Of the total submissions, 99.4% included effectiveness critiques, 88.8% included model structure critiques, 69.1% included utility score critiques, and 78.7% included cost critiques. The median incremental cost-utility ratio (ICUR) in the manufacturers’ analyses was $138,658/quality-adjusted life-year (QALY), 2.5-fold lower than the CADTH’s reanalysis at $380,251/QALY (p

Date: 2024
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-024-00511-9 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:8:y:2024:i:6:d:10.1007_s41669-024-00511-9

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-024-00511-9

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().